Lexicon Pharmaceuticals, Inc. LXRX
What this company does
Written from the business description in Lexicon Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at +16.3% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 40 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | 0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.0 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | 0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| Income tax $B | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.2 | −0.2 | 0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −0.14 | −0.63 | −0.80 | −0.62 | −0.60 | −0.53 | 1.16 | −1.14 | −1.17 | −1.27 | −0.05 | −1.31 | −1.42 | −0.23 | −0.34 | −0.34 | −0.57 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −39.7 | −167.7 | −168.5 | −88.4 | −65.0 | −42.8 | 287.0 | −576.0 | −104.3 | −58.0 | −1.6 | −44.2 | −47.7 | −39.1 | −42.7 | −41.2 | · |
| Shares out B | 0.37 | 0.36 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 16 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 19 checks could not be computed.